Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2017

Published: Apr, 2017 | Pages: 187 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 21, 11, 1, 19, 5 and 1 respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Keratoconjunctivitis sicca (Dry Eye) - Overview 8
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Products under Development by Companies 14
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 28
Aldeyra Therapeutics Inc 28
Allergan Plc 28
Ascendia Pharmaceuticals LLC 29
BioLineRx Ltd 29
Cambium Medical Technologies LLC 30
Chong Kun Dang Pharmaceutical Corp 30
Dompe Farmaceutici SpA 31
Elasmogen Ltd 31
HanAll Biopharma Co Ltd 32
Herantis Pharma Plc 32
Huons Co Ltd 33
InSite Vision Inc 33
Kala Pharmaceuticals Inc 34
KPI Therapeutics Inc 34
Kukje Pharmaceutical Industry Co Ltd 35
Laboratoires Thea SA 35
Lipicard Technologies Ltd 36
Merck & Co Inc 36
Mimetogen Pharmaceuticals Inc 37
Mitotech SA 37
Nanomerics Ltd 38
Nemus Bioscience Inc 38
Neuroptis Biotech 39
Novaliq GmbH 39
Ocular Therapeutix Inc 40
Oculis ehf 40
OncoNOx ApS 41
Otsuka Holdings Co Ltd 41
Parion Sciences Inc 42
Quorum Innovations LLC 42
RegeneRx Biopharmaceuticals Inc 43
Samjin Pharmaceutical Co Ltd 43
Santen Pharmaceutical Co Ltd 44
Seikagaku Corp 44
Shire Plc 45
Sun Pharmaceutical Industries Ltd 45
TearSolutions LLC 46
TopiVert Ltd 46
Vanda Pharmaceuticals Inc 47
Xigen SA 47
Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles 48
ADX-102 - Drug Profile 48
ADX-103 - Drug Profile 53
AGN-195263 - Drug Profile 54
AGN-223575 - Drug Profile 55
AGN-232411 - Drug Profile 56
AL-41A1 - Drug Profile 57
Androgen Tears - Drug Profile 58
AVA-3486 - Drug Profile 59
AVX-012 - Drug Profile 60
AX-1606 - Drug Profile 61
BL-1230 - Drug Profile 62
BRM-421 - Drug Profile 63
cenegermin - Drug Profile 64
cinhyaluronate sodium - Drug Profile 67
Cis-Urocanic Acid - Drug Profile 68
cyclosporine - Drug Profile 70
cyclosporine - Drug Profile 73
cyclosporine - Drug Profile 75
cyclosporine - Drug Profile 76
cyclosporine - Drug Profile 77
cyclosporine - Drug Profile 78
cyclosporine - Drug Profile 79
cyclosporine SR - Drug Profile 80
dexamethasone acetate SR - Drug Profile 81
diclofenac sodium - Drug Profile 87
diquafosol tetrasodium - Drug Profile 88
Drug for Dry Eye - Drug Profile 90
Drugs to Agonize FPR2 for Dry Eye - Drug Profile 91
Elate Ocular - Drug Profile 92
ELN-22 - Drug Profile 93
HL-036 - Drug Profile 94
HU-007 - Drug Profile 95
hyaluronate sodium - Drug Profile 96
ISV-101 - Drug Profile 97
K-089 - Drug Profile 98
KeraKlear - Drug Profile 99
KJ-14003 - Drug Profile 100
KJ-16001 - Drug Profile 101
KL-7016 - Drug Profile 102
KPI-190 - Drug Profile 103
Lacripep - Drug Profile 104
Leukothera - Drug Profile 105
lifitegrast - Drug Profile 107
LME-636 - Drug Profile 111
loteprednol etabonate - Drug Profile 112
LT-4002 - Drug Profile 115
LT-4003 - Drug Profile 116
NB-2222 - Drug Profile 117
NOP-3 - Drug Profile 118
NOP-5 - Drug Profile 119
Nov-03 - Drug Profile 120
OC-301 - Drug Profile 121
OTX-101 - Drug Profile 122
OX-1001 - Drug Profile 124
P-321 - Drug Profile 125
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 127
PPL-003 - Drug Profile 129
Protearin - Drug Profile 131
Qi-401 - Drug Profile 132
rebamipide - Drug Profile 133
RGN-259 - Drug Profile 135
RP-101 - Drug Profile 142
SA-001 - Drug Profile 143
SJP-002 - Drug Profile 144
Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile 145
solithromycin - Drug Profile 146
ST-266 - Drug Profile 160
tadekinig alfa - Drug Profile 162
tavilermide hydrochloride - Drug Profile 163
TOP-1630 - Drug Profile 165
XG-104 - Drug Profile 166
zucapsaicin - Drug Profile 167
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 169
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 173
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 174
Featured News & Press Releases 174
Appendix 181
Methodology 181
Coverage 181
Secondary Research 181
Primary Research 181
Expert Panel Validation 181
Contact Us 181
Disclaimer 182

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by BioLineRx Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Elasmogen Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech SA, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nemus Bioscience Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corp, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sun Pharmaceutical Industries Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions LLC, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Vanda Pharmaceuticals Inc, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H1 2017